Top Page
Blue Jet Healthcare Limited
(BLUEJET)
Blue Jet Healthcare Limited (BLUEJET) vs. iShares MSCI India ETF (INDA)
Blue Jet Healthcare Limited Business Overview & Revenue Model
Blue Jet Healthcare Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.22B | 10.30B | 7.10B | 7.18B | 6.77B | 4.94B |
| Gross Profit | 6.32B | 5.69B | 3.89B | 2.70B | 2.97B | 2.47B |
| EBITDA | 4.88B | 4.24B | 2.48B | 2.43B | 2.69B | 2.15B |
| Net Income | 3.59B | 3.05B | 1.64B | 1.60B | 1.82B | 1.38B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 14.18B | 10.59B | 8.62B | 7.13B | 5.36B |
| Cash, Cash Equivalents and Short-Term Investments | 3.06B | 3.06B | 3.09B | 2.55B | 1.81B | 979.70M |
| Total Debt | 0.00 | 199.86M | 16.13M | 34.40M | 173.17M | 516.15M |
| Total Liabilities | -11.33B | 2.84B | 2.14B | 1.81B | 1.92B | 1.96B |
| Stockholders Equity | 11.33B | 11.33B | 8.45B | 6.81B | 5.22B | 3.40B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -341.15M | 669.59M | 822.79M | 1.21B | 807.67M |
| Operating Cash Flow | 0.00 | 457.65M | 2.41B | 1.42B | 1.46B | 1.30B |
| Investing Cash Flow | 0.00 | -351.83M | -2.64B | -1.47B | -760.26M | -566.48M |
| Financing Cash Flow | 0.00 | -185.57M | -19.86M | -42.33M | -561.45M | -221.90M |
Blue Jet Healthcare Limited Technical Analysis
Blue Jet Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ₹257.22B | 50.51 | ― | 0.19% | 7.41% | 2.88% | |
| ― | ₹60.52B | 33.69 | ― | 0.13% | 13.68% | 31.69% | |
| ― | ₹112.34B | 31.53 | ― | 0.18% | 75.82% | 127.81% | |
| ― | ₹111.11B | 37.79 | ― | 0.72% | 3.80% | 64.94% | |
| ― | ₹160.40B | 45.04 | ― | 0.73% | 14.49% | 13.70% | |
| ― | ₹503.08B | 116.54 | ― | 0.13% | 6.80% | -75.66% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Blue Jet Healthcare Limited Corporate Events
Blue Jet Healthcare Limited has announced that it has complied with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, as confirmed by its Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The company stated that all its shares are held in dematerialized form, and no requests for rematerialization were received during the quarter ended September 30, 2025, indicating streamlined operations and compliance with regulatory requirements.
Blue Jet Healthcare Limited held its 57th Annual General Meeting on September 26, 2025, through video conferencing, in compliance with regulatory guidelines. The meeting was chaired by Mr. Akshay Bansarial Arora and attended by all directors and committee chairpersons. Key topics included the company’s strategies and performance for FY 2024-25, with all necessary documents made available for electronic inspection. The Auditor’s Report was accepted without any qualifications or adverse remarks.
Blue Jet Healthcare Limited has announced its participation in the Kotak Healthcare Forum, scheduled for September 19, 2025, where it will engage in a one-to-one investor meeting. This engagement is part of the company’s efforts to maintain transparency with its stakeholders, ensuring that no unpublished price-sensitive information is disclosed during the meeting.
Blue Jet Healthcare Limited announced several key decisions following its board meeting on August 22, 2025. The company has appointed M/s. Mehta & Mehta as its secretarial auditors for five years and re-appointed Mr. Naresh Suryakant Shah as a Whole-Time Director for another five-year term. Additionally, Mr. Popat Bhagwan Kedar has been re-designated as a Whole-Time Director for a similar period. The company has set a record date of September 19, 2025, for dividend entitlement and scheduled its 57th Annual General Meeting for September 26, 2025. These decisions are expected to strengthen the company’s governance and operational continuity, potentially enhancing shareholder value.
Blue Jet Healthcare Limited announced significant changes in its board of directors, including the appointment of Mehta & Mehta as Secretarial Auditors for five years and the re-appointment of Mr. Naresh Suryakant Shah and re-designation of Mr. Popat Bhagwan Kedar as Whole-Time Directors. Additionally, the company declared a final dividend of Rs. 1.2 per equity share and scheduled its 57th Annual General Meeting for September 26, 2025, indicating a strategic focus on governance and shareholder value.
Blue Jet Healthcare Limited announced significant changes in its corporate governance and financial operations following a board meeting. The company appointed M/s. Mehta & Mehta as Secretarial Auditors for a five-year term, re-appointed Mr. Naresh Suryakant Shah as Whole-Time Director, and re-designated Mr. Popat Bhagwan Kedar as Whole-Time Director, all subject to shareholder approval. Additionally, the company declared a dividend of Rs. 1.2 per share and scheduled its 57th Annual General Meeting for September 26, 2025.
Blue Jet Healthcare Limited, a company listed on the BSE and NSE, announced several key decisions following its board meeting on August 22, 2025. The board approved the appointment of M/s. Mehta & Mehta as Secretarial Auditors for a five-year term and re-appointed Mr. Naresh Suryakant Shah and re-designated Mr. Popat Bhagwan Kedar as Whole-Time Directors for five years, subject to shareholder approval. Additionally, the company set September 19, 2025, as the record date for a dividend of Rs. 1.2 per share, with payment due by October 25, 2025. The 57th Annual General Meeting is scheduled for September 26, 2025.
Blue Jet Healthcare Limited has announced the acquisition of a 102.48-acre industrial land parcel in Andhra Pradesh, as part of its strategy to expand manufacturing capacity. This move aligns with the company’s long-term growth objectives and is expected to enhance its production capabilities across key therapeutic platforms, potentially strengthening its market position.